NEW YORK (GenomeWeb) – In a filing with the US Securities and Exchange Commission, Genomic Health reported a $3.2 million realized gain in 2016 from a sale of equity securities in connection with the sale of a portion of its Invitae stock holdings. The company further sold all its remaining shares in Invitae in January 2017 for $10.2 million, resulting in a realized gain of $2.8 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.